JOURNAVX (Suzetrigine)

JOURNAVX (suzetrigine), from Vertex, was approved by the FDA on 30 January 2025 as the first new class of pain medicine in more than two decades. It treats moderate to severe acute pain in adults, including pain after surgery, and is not an opioid or controlled substance.

Suzetrigine selectively blocks the NaV1.8 sodium channel on peripheral pain-sensing nerves, stopping pain signals before they reach the brain, without the addictive potential of opioids. Treatment starts with 100 mg on an empty stomach, followed by 50 mg every 12 hours, for the shortest time needed.

• Contraindicated with strong CYP3A inhibitors; the dose must be reduced with moderate CYP3A inhibitors, and grapefruit should be avoided.
• Avoid in severe liver impairment; a lower dose is used in moderate impairment. It may reduce the effectiveness of some hormonal contraceptives.
• Common side effects include itching, muscle spasms, raised creatine phosphokinase and rash.

Can JOURNAVX be imported to India?

Yes. JOURNAVX is approved in the US. With a doctor’s prescription, it can be imported in the patient’s name under the named-patient route.

How is JOURNAVX taken?

The US label starts with a single 100 mg dose (two 50 mg tablets) on an empty stomach, at least 1 hour before or 2 hours after food. From 12 hours later, 50 mg is taken every 12 hours, with or without food. It is used for the shortest time needed; it has not been studied for acute pain beyond 14 days.

What documents do we need?

• A prescription from the treating doctor stating the dose and duration
• A short clinical note on the acute pain being treated (for example, after surgery)
• Government-issued photo ID of the patient (or the hospital’s details for hospital orders)

We confirm the order only after the prescription or requisition has been checked.

What pack sizes are there and how is it stored?

In the US, JOURNAVX 50 mg tablets come in bottles of 30 or 100 (and a 100-tablet hospital pack). Store at 20–25 °C, with short excursions between 15 and 30 °C allowed.

A short post-surgical course is usually covered by one 30-tablet bottle; we can advise on quantity once we see the prescription. IPN sources JOURNAVX through authorised US distribution.

For JOURNAVX price in India, call +91 96548 60915 or +91 93100 90915, WhatsApp +91 98104 69557 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: FDA-approved — 30 January 2025.
• European Union / Japan: Not approved as of October 2026.

Sources:

• JOURNAVX US Prescribing Information (Vertex, revised 1/2026)
• JOURNAVX label on DailyMed (US National Library of Medicine)

Information last checked: October 2026.

Why is JOURNAVX used?

Doctors prescribe JOURNAVX for moderate to severe acute pain in adults. It is a first-in-class non-opioid NaV1.8 pain-signal inhibitor.

Who is the maker of JOURNAVX?

It is made by Vertex Pharmaceuticals.

How does Suzetrigine act in the body?

Suzetrigine selectively blocks the NaV1.8 sodium channel on peripheral pain-sensing nerves, stopping pain signals before they reach the brain, without the addictive potential of opioids.

Is JOURNAVX addictive?

It is a non-opioid and is not classified as a controlled substance in the US.

Can I drink grapefruit juice with JOURNAVX?

No. The label says food or drink containing grapefruit should be avoided during treatment.

Is JOURNAVX FDA approved?

Yes. The FDA approved JOURNAVX in January 2025.